Natera Inc.: An Insight Into Its Strategic Collaborations, AI Initiatives & Other Major Drivers!

Natera reported a promising financial and operational performance for Q2 2025. The company’s revenue reached $547 million, representing a 32% year-on-year increase, which, when excluding revenue adjustments, marked an organic growth of 34%. This performance was bolstered by substantial demand for its oncology products, particularly Signatera, which saw a record of 189,000 processed tests during the quarter. This result was encouraged by a notable increase in new patient starts, essentially doubling previous records. Gross margins have also improved, climbing to 63.4% from around 59% in the same period last year, despite a rise in cost of goods sold due to increased volumes.